149 related articles for article (PubMed ID: 37596667)
1. NEK8 regulates colorectal cancer progression via phosphorylating MYC.
Cao B; Zhang K; Pan C; Dong Y; Lu F
Cell Commun Signal; 2023 Aug; 21(1):209. PubMed ID: 37596667
[TBL] [Abstract][Full Text] [Related]
2. Mutations in NEK8 link multiple organ dysplasia with altered Hippo signalling and increased c-MYC expression.
Frank V; Habbig S; Bartram MP; Eisenberger T; Veenstra-Knol HE; Decker C; Boorsma RA; Göbel H; Nürnberg G; Griessmann A; Franke M; Borgal L; Kohli P; Völker LA; Dötsch J; Nürnberg P; Benzing T; Bolz HJ; Johnson C; Gerkes EH; Schermer B; Bergmann C
Hum Mol Genet; 2013 Jun; 22(11):2177-85. PubMed ID: 23418306
[TBL] [Abstract][Full Text] [Related]
3. Kinase GSK3β functions as a suppressor in colorectal carcinoma through the FTO-mediated MZF1/c-Myc axis.
Zhang Z; Gao Q; Wang S
J Cell Mol Med; 2021 Mar; 25(5):2655-2665. PubMed ID: 33533172
[TBL] [Abstract][Full Text] [Related]
4. Disruption of the c-Myc/miR-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer.
Lv Z; Wei J; You W; Wang R; Shang J; Xiong Y; Yang H; Yang X; Fu Z
J Transl Med; 2017 Dec; 15(1):257. PubMed ID: 29258530
[TBL] [Abstract][Full Text] [Related]
5. Significant position of C-myc in colorectal cancer: a promising therapeutic target.
Tan L; Peng D; Cheng Y
Clin Transl Oncol; 2022 Dec; 24(12):2295-2304. PubMed ID: 35972682
[TBL] [Abstract][Full Text] [Related]
6. CIP2A regulates MYC translation (via its 5'UTR) in colorectal cancer.
Denk S; Schmidt S; Schurr Y; Schwarz G; Schote F; Diefenbacher M; Armendariz C; Dejure F; Eilers M; Wiegering A
Int J Colorectal Dis; 2021 May; 36(5):911-918. PubMed ID: 33078202
[TBL] [Abstract][Full Text] [Related]
7. STK16 promoted colorectal cancer progress in a c-MYC signaling-dependent manner.
Peng L; Guangshi L; Wusman LB; Tao L
Mol Med; 2024 Apr; 30(1):50. PubMed ID: 38622518
[TBL] [Abstract][Full Text] [Related]
8. Metformin blocks MYC protein synthesis in colorectal cancer via mTOR-4EBP-eIF4E and MNK1-eIF4G-eIF4E signaling.
Shen P; Reineke LC; Knutsen E; Chen M; Pichler M; Ling H; Calin GA
Mol Oncol; 2018 Nov; 12(11):1856-1870. PubMed ID: 30221473
[TBL] [Abstract][Full Text] [Related]
9. Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistance.
Pranteda A; Piastra V; Serra M; Bernardini R; Lo Sardo F; Carpano S; Diodoro MG; Bartolazzi A; Milella M; Blandino G; Bossi G
Biomed Pharmacother; 2023 Nov; 167():115480. PubMed ID: 37713993
[TBL] [Abstract][Full Text] [Related]
10. BMAL1 promotes colorectal cancer cell migration and invasion through ERK- and JNK-dependent c-Myc expression.
Shan L; Zheng W; Bai B; Hu J; Lv Y; Chen K; Wang X; Pan Y; Huang X; Zhu H; Dai S
Cancer Med; 2023 Feb; 12(4):4472-4485. PubMed ID: 36806631
[TBL] [Abstract][Full Text] [Related]
11. Deptor Is a Novel Target of Wnt/β-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth.
Wang Q; Zhou Y; Rychahou P; Harris JW; Zaytseva YY; Liu J; Wang C; Weiss HL; Liu C; Lee EY; Evers BM
Cancer Res; 2018 Jun; 78(12):3163-3175. PubMed ID: 29666061
[TBL] [Abstract][Full Text] [Related]
12. Mission Possible: Advances in MYC Therapeutic Targeting in Cancer.
Allen-Petersen BL; Sears RC
BioDrugs; 2019 Oct; 33(5):539-553. PubMed ID: 31392631
[TBL] [Abstract][Full Text] [Related]
13. Gene variants of TCF7L2 are histopathologically important in colorectal cancers but do not have direct association with MYC expression.
Ozkan Kucuk NE; Horozoglu C; Timirci Kahraman O; Arikan S; Farooqi AA; Turan S; Korkmaz G; Kelten Talu EC; Sabitaliyevich UY; Yaylim I
Cell Mol Biol (Noisy-le-grand); 2019 Dec; 65(8):1-6. PubMed ID: 32133972
[TBL] [Abstract][Full Text] [Related]
14. miR-181d and c-myc-mediated inhibition of CRY2 and FBXL3 reprograms metabolism in colorectal cancer.
Guo X; Zhu Y; Hong X; Zhang M; Qiu X; Wang Z; Qi Z; Hong X
Cell Death Dis; 2017 Jul; 8(7):e2958. PubMed ID: 28749470
[TBL] [Abstract][Full Text] [Related]
15. Targeting Myc-driven stress addiction in colorectal cancer.
Saeed H; Leibowitz BJ; Zhang L; Yu J
Drug Resist Updat; 2023 Jul; 69():100963. PubMed ID: 37119690
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Omics Analysis of a Novel Small-Molecule Inhibitor of Chemoresistant Oncogenic Signatures in Colorectal Cancer Cell with Antitumor Effects.
Huang TH; Mokgautsi N; Huang YJ; Wu ATH; Huang HS
Cells; 2021 Aug; 10(8):. PubMed ID: 34440739
[TBL] [Abstract][Full Text] [Related]
17. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
[TBL] [Abstract][Full Text] [Related]
18. microRNA-96 promotes occurrence and progression of colorectal cancer via regulation of the AMPKα2-FTO-m6A/MYC axis.
Yue C; Chen J; Li Z; Li L; Chen J; Guo Y
J Exp Clin Cancer Res; 2020 Nov; 39(1):240. PubMed ID: 33183350
[TBL] [Abstract][Full Text] [Related]
19. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
20. Human UTP14a promotes colorectal cancer progression by forming a positive regulation loop with c-Myc.
Zhang J; Ren P; Xu D; Liu X; Liu Z; Zhang C; Li Y; Wang L; Du X; Xing B
Cancer Lett; 2019 Jan; 440-441():106-115. PubMed ID: 30343112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
